维布妥昔单抗联合IGE方案治疗儿童复发或难治经典型霍奇金淋巴瘤的临床研究
该病例系列研究纳入23例复发或难治经典型霍奇金淋巴瘤患儿,接受维布妥昔单抗联合异环磷酰胺、吉西他滨方案化疗,评估有效性与安全性。结果显示2周期后22例可评估患儿均有响应,14例(64%)获代谢学完全缓解,总CMR率91%(21/23),21例免于造血干细胞移植;≥3级不良事件以骨髓抑制为主,未影响序贯治疗。
要点
- BV联合IGE方案在儿童复发或难治cHL中疗效显著,总CMR率91%(21/23)。
- 21例(91%)患儿免于造血干细胞移植,3例接受BV单药维持。
- ≥3级不良事件以骨髓抑制为主,均未影响后续序贯治疗。
核心结论
- BV联合IGE方案治疗儿童复发或难治cHL疗效显著、安全性可耐受,并可降低造血干细胞移植比例。
研究设计与样本
- 病例系列研究,纳入2022年6月至2025年8月首都医科大学附属北京儿童医院诊治的23例复发或难治cHL患儿,均接受1~4个周期BV联合IGE方案化疗,随访至2025年12月31日。
主要发现
- 23例中男16例、女7例,年龄14.8(12.1,16.7)岁;原发难治3例,复发20例。
- 22例可评估患儿2个周期化疗后均有响应,14例(64%)获得CMR。
- 23例随访15(9,24)个月均无事件生存,总CMR率为91%(21/23)。
- 累计完成84个周期化疗,化疗后均行受累野放疗,21例免于造血干细胞移植,3例接受BV单药维持。
- 共记录144例次≥3级不良事件,以骨髓抑制为主,均未影响序贯治疗;血清IgA、IgG、IgM治疗前后均在正常范围。
关键数值与推荐
- 治疗前总B细胞计数166×10⁶(38×10⁶,259×10⁶)/L,治疗期间降至17×10⁶(5×10⁶,21×10⁶)/L,化疗后3个月恢复至214×10⁶(142×10⁶,266×10⁶)/L。
- 自然杀伤细胞和总T细胞计数治疗前均减低,治疗期间进一步下降,化疗后6和9个月分别恢复至治疗前基线水平。
临床怎么用
- 对于儿童复发或难治cHL,可考虑BV联合IGE方案化疗后序贯受累野放疗,以减少造血干细胞移植需求。
- 治疗期间需监测骨髓抑制等不良事件及B细胞、NK细胞、T细胞计数变化,但不良事件多不影响序贯治疗。
局限性
- 本研究为单中心病例系列研究,样本量23例,随访时间15(9,24)个月,尚需更长期随访及对照研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To evaluate the efficacy and safety of brentuximab vedotin (BV) combined with the IGE regimen (ifosfamide, gemcitabine) in the treatment of children's relapsed or refractory classic Hodgkin lymphoma (cHL). Methods: In this case series study, clinical data including age, sex, symptoms, pathological sub-type, clinical stage, previous clinical stage and treatment of the relapsed or refractory cHL children diagnosed and treated at Beijing Children's Hospital Affiliated to Capital Medical University from June 2022 to August 2025 were collected. All 23 children received 1 to 4 cycles of chemotherapy with BV plus the IGE regimen. Children were followed up until December 31st, 2025, and infusion reactions during treatment and adverse reactions after administration were recorded. Results: Among 23 children, there were 16 males and 7 females, the age was 14.8 (12.1, 16.7) years, and there were 3 children of refractory and 20 children of relapsed cHL. Pathological sub-types included 13 children of nodular sclerosis, 1 child of lymphocyte depletion, 7 children of mixed cellularity, and 2 children of lymphocyte-rich type. At initial diagnosis, 3 children presented with stage Ⅱ, 8 with stage Ⅲ, and 12 with stage Ⅳ. All 23 children received chemotherapy, among whom 14 had prior radiotherapy, 3 had programmed death 1 inhibitor treatment (1 of whom underwent autologous hematopoietic stem cell transplantation). At relapse or refractory disease, clinical stage was stage Ⅱ in 5 children, stage Ⅲ in 4 children, and stage Ⅳ in 14 children. A total of 84 cycles of BV combined with IGE regimen chemotherapy were administered. All children received involved-field radiotherapy after chemotherapy. Twenty-one children avoided hematopoietic stem cell transplantation, and 3 received single-agent BV maintenance therapy. All 22 evaluable children achieved a treatment response after 2 cycles of chemotherapy, and 14 (64%) achieved complete metabolic response (CMR). The follow-up time was 15 (9, 24) months; all 23 children achieved event-free survival, with an overall CMR rate of 91% (21/23). A total of 144 cases of grade 3 or above adverse events were recorded, predominantly myelosuppression, and none of which affected subsequent sequential treatment. Serum immunoglobulin levels (IgA, IgG, IgM) in children remained within the normal range before and after treatment. The pre-treatment total B-cell count was 166×10⁶ (38×10⁶, 259×10⁶)/L, which decreased to 17×10⁶ (5×10⁶, 21×10⁶)/L during treatment and recovered to 214×10⁶ (142×10⁶, 266×10⁶)/L at 3 months post-chemotherapy. Both natural killer cells and total T-cell counts were reduced at baseline, declined further during therapy, and returned to pre-treatment baseline levels at 6 months and 9 months after chemotherapy, respectively. Conclusion: BV combined with the IGE regimen has demonstrated marked efficacy and a favorable tolerable safety profile in the treatment of relapsed or refractory cHL in children while reducing the proportion of patients requiring hematopoietic stem cell transplantation. 目的: 评估维布妥昔单抗(BV)联合IGE方案(异环磷酰胺、吉西他滨)治疗儿童复发或难治经典型霍奇金淋巴瘤(cHL)的有效性及安全性。 方法: 病例系列研究。收集2022年6月至2025年8月首都医科大学附属北京儿童医院诊治的23例复发或难治cHL患儿的临床资料,包括年龄、性别、症状、病理亚型、临床分期、既往临床分期及治疗情况等。23例患儿均接受1~4个周期BV联合IGE方案化学治疗(简称化疗)。随访至2025年12月31日,记录用药期间有无输注反应及用药后的不良事件。 结果: 23例复发或难治cHL患儿中男16例、女7例,年龄14.8(12.1,16.7)岁;原发难治3例,复发20例;结节硬化型13例,淋巴细胞消减型1例,混合细胞型7例,富于淋巴细胞型2例。初治时临床分期Ⅱ期3例,Ⅲ期8例,Ⅳ期12例;23例均曾接受化疗,14例曾接受放射治疗,3例曾接受程序性死亡受体1抑制剂治疗(其中1例曾接受自体造血干细胞移植)。复发或难治阶段临床分期Ⅱ期5例,Ⅲ期4例,Ⅳ期14例。累计完成84个周期BV联合IGE方案化疗,化疗结束后均进行了受累野放射治疗,21例免于造血干细胞移植,3例接受了BV单药维持治疗。22例患儿2个周期化疗后评估治疗均有响应,14例(64%)获得代谢学完全缓解(CMR)。23例患儿随访15(9,24)个月,均无事件生存,CMR率为91%(21/23)。共记录到144例次≥3级的不良事件,以骨髓抑制为主,均未影响序贯治疗。监测患儿治疗前后血清免疫球蛋白IgA、IgG、IgM水平均在正常范围;治疗前总B细胞计数166×106(38×106,259×106)/L,治疗期间下降至17×106(5×106,21×106)/L,化疗后3个月时恢复至214×106(142×106,266×106)/L;自然杀伤细胞和总T细胞计数治疗前均减低,治疗期间进一步下降,化疗后6和9个月时分别恢复至治疗前基线水平。 结论: BV联合IGE方案治疗儿童复发或难治cHL疗效显著,安全性可耐受,可显著降低造血干细胞移植比例。.
引用
- Zhang M, Li N, Huang S, et al. [Clinical study of brentuximab vedotin combined with the ifosfamide and gemcitabine regimen in the treatment of children with relapsed or refractory classic Hodgkin lymphoma]. Zhonghua Er Ke Za Zhi. 2026. PMID: 42605090. doi:10.3760/cma.j.cn112140-20260123-00076
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。